Psilocybin and Psychological Support: A New Approach for Veterans and First Responders

James, 42, sits in a VA hospital room, his hands shaking as he talks about a night of drinking to keep the memories of a battlefield explosion at bay. He’s not alone — over 200,000 veterans and first responders in the U.S. live with both posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD), a deadly combination that often leads to early death. Traditional treatments have struggled to break the cycle. Now, a new study is asking if psilocybin, paired with psychological support, might be the missing link.

Bottom line: This phase 2 trial examines whether psilocybin with psychological support (Psi-PS) is safe and effective for veterans and first responders with co-occurring PTSD and AUD — a population that has historically been overlooked in psychedelic research.

The Double-Edged Sword of PTSD and AUD

For veterans and first responders, the intersection of PTSD and AUD isn’t just a statistical overlap — it’s a cycle that can be hard to break. PTSD, triggered by trauma, brings flashbacks, nightmares, and emotional dysregulation. AUD, often used as a coping mechanism, numbs the pain but makes PTSD symptoms worse. The feedback loop is clear: alcohol use worsens PTSD symptoms, while PTSD makes AUD harder to quit.

This study focuses on a group that has been largely ignored in psychedelic research. Most trials have targeted patients with single diagnoses, not the complex, intertwined conditions that veterans and first responders often face. The hypothesis is simple: what if a single treatment could address both disorders at once?

The trial is a phase 2, double-blind, placebo-controlled study with an open-label extension. Participants are randomly assigned to receive either psilocybin (25 mg) or a placebo (maltodextrin), both combined with psychological support. The support is not structured therapy. It’s about presence — safety, reassurance, active listening, and empathetic presence — delivered in a non-directive way. The idea is to create a space where participants can process trauma without judgment or pressure.

This is a shift from traditional psychedelic research, which often relies on therapists to guide the experience. Here, the psychological support is more about being there than directing the journey. It could make the treatment more accessible and less intimidating for those who have already endured years of trauma.

Safety First: The Primary Goal of the Study

The primary objective is to assess the safety of psilocybin combined with psychological support for individuals with co-occurring PTSD and AUD. This is a key focus, given the high risk of adverse effects in this population. Traditional treatments for AUD, like naltrexone or acamprosate, have limited efficacy, and many veterans and first responders struggle with comorbid conditions that complicate treatment.

The study plans to recruit about 40 participants, aged 21 to 65, who meet criteria for both PTSD and AUD. The placebo group allows researchers to separate the effects of psilocybin from the psychological support. By comparing outcomes between the two groups, the study can determine whether psilocybin itself, or the combination with support, is responsible for any changes.

Safety is a top priority, and the study includes rigorous monitoring for adverse events, both acute and long-term. Participants are closely observed during and after the psilocybin sessions. Follow-up assessments track progress over time. The researchers are particularly interested in how the combination affects participants’ ability to engage in therapy, reduce alcohol use, and manage PTSD symptoms.

This focus on safety isn’t just about avoiding harm — it’s about understanding the full spectrum of psilocybin’s potential. The study is part of growing research suggesting psychedelics may have therapeutic applications beyond mental health, including addiction treatment and trauma recovery. But for these results to be meaningful, they must be grounded in rigorous science.

A Bold Hypothesis: Treating Two Disorders at Once

The researchers behind this study are betting that psilocybin, when paired with psychological support, can address the root causes of both PTSD and AUD. It’s a bold hypothesis, especially in a population where traditional treatments have often fallen short.

The rationale is that psilocybin may help participants access repressed memories and emotions, often at the heart of both conditions. By facilitating a deeper connection to trauma, psilocybin could help processing in a way that traditional therapy might not. The psychological support provides a safe space for this kind of processing, allowing participants to confront their trauma without fear of judgment.

But the study has challenges. One is preparing participants for the experience. The psychological support is designed to help them navigate the intensity of a psilocybin session, especially for those with a history of trauma or dissociation.

Another challenge is the potential for adverse reactions. While psilocybin is generally safe in controlled settings, the combination of PTSD and AUD may increase the risk of certain side effects. The study is designed to monitor these risks closely and adjust treatment as needed.

Despite these challenges, the researchers are optimistic. They believe the combination could offer a new treatment option for veterans and first responders. If successful, the study could pave the way for larger trials that explore the full potential of psychedelics in treating complex mental health conditions.

Frequently Asked Questions

Q: Is this study about treating PTSD or AUD alone?
A: No. This study focuses on individuals with co-occurring PTSD and AUD. Researchers are examining whether psilocybin, combined with psychological support, can address both conditions simultaneously.

Q: How is psychological support defined in this study?
A: Psychological support is defined as providing safety, reassurance, active listening, and empathetic presence during the psilocybin session. It is delivered in a non-directive manner, meaning it does not involve structured therapy or guidance.

Q: What dose of psilocybin does this study use?
A: The study uses a single dose of psilocybin at 25 mg, considered a low to moderate dose. This amount was chosen to balance therapeutic potential with safety.

Q: Are there any known risks associated with psilocybin use in this population?
A: While psilocybin is generally safe in controlled settings, the combination of PTSD and AUD may increase the risk of certain side effects. The study is designed to monitor these risks closely and adjust the treatment as needed.

Q: What happens after the study is completed?
A: The study includes an open-label extension phase, allowing participants to continue receiving psilocybin and psychological support if they choose. Researchers are also planning future studies that will expand the sample size and include a more diverse group of participants.

Sources

• ¶ClinicalTrials.gov – NCT06853912
• ¶Nathan Brashares Sackett – Sponsor
• ¶Psilocybin and PTSD: A Review
• ¶Alcohol Use Disorder and PTSD: A Dual Diagnosis
• ¶Psychedelic Therapy for Trauma and Addiction

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.